Colossal Biosciences Targets Thirty Billion Dollar Valuation as De-Extinction Tech Monetizes

By Marina Temkin · TechCrunch · 2026-07-20

TechCrunch reports that Dallas-based Colossal Biosciences is currently negotiating a fresh capital injection that could triple its previous valuation. The five-year-old firm is successfully pivoting from pure research into a revenue-generating entity by licensing conservation too

TechCrunch reports that Dallas-based Colossal Biosciences is currently negotiating a fresh capital injection that could triple its previous valuation. The five-year-old firm is successfully pivoting from pure research into a revenue-generating entity by licensing conservation too